drugset / Trial / NCT05658016
Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690
RandomizedParallel-groupTriple-blindPrevention
Summary
Patients expected to receive a continuous course of radiation as single daily fractions of 2.0 Gy treatment with a cumulative radiation dose of 70 Gy. The radiation can be 2DRT, 3DRT,IMRT etc. Prior to each radiation treatment the patients will receive a one-hour infusion of TK-90 or equivalent TK-90 placebo depending on randomization. 6 Hours after the completion of TK-90 infusion or TK-90 placebo dose, the patients will receive another identical TK-90 or TK-90 placebo treatment depending on randomization. This treatment cycle will continue for 7 weeks. The TK112690 dose will be 45 mg/kg.
Timeline
- Start
- 2022-06-17
- Primary completion
- 2023-09
- Completion
- 2023-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TK-112690 | Small molecule | 45 mg/kg | Other |